21st September 2010

Company Announcements Office
Australian Securities Exchange

Nanosonics and GE Healthcare sign distribution agreement for the distribution of Trophon EPR in USA and Canada

Australia, 21st September 2010 – Nanosonics Limited (ASX:NAN) and GE Healthcare (GEHC), a division of The General Electric Company (NYSE:GE), announced today a distribution agreement providing GEHC with exclusive distribution rights for Nanosonics' Trophon® EPR ultrasound probe disinfector and its consumables in USA and Canada. The agreement also provides GE Healthcare non-exclusive OEM co-sales of the Trophon EPR with GEHC ultrasound consoles in other countries outside the USA and Canada. Whilst details of the agreement are commercial in confidence, and further details of the alliance are still being discussed, Nanosonics and GEHC have agreed to target conclusion of a definitive distribution agreement over the next 30 days

"The proposed alliance with GE Healthcare represents Nanosonics' accomplishment, on schedule, of its next major step toward the sale of Trophon EPR and its consumables in North America, the world's largest market for ultrasound equipment," said David Radford, CEO of Nanosonics. "Nanosonics' 510(k) application to the FDA remains on track, with its previously anticipated timelines. Distribution in the US market will commence following FDA clearance of the Trophon EPR and its consumable."

GEHC is the leading supplier of ultrasound equipment in USA and Canada, and has global market leadership in key obstetric/gynaecological applications. This alliance between GEHC and Nanosonics also provides for further product development opportunities to address the needs of GEHC's customers worldwide.

As previously announced, in preparation for the launch of Trophon into the US market in early 2011, Nanosonics is scaling-up its capacity for a US-specified device.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.
For more information about Nanosonics please visit www.nanosonics.com.au

About GE Healthcare:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $16 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website: gehealthcare.com.

For more information please contact:
David Radford, CEO Nanosonics or Chris Grundy, CFO & Company Secretary, on 61-2 8063 1600